Vertex Pharmaceuticals (VRTX)’ povetacicept was granted FDA orphan designation as a treatment of membranous nephropathy, according to a post to the agency’s website.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex upgraded to Outperform from Sector Perform at RBC Capital
- Maze Therapeutics price target raised to $46 from $37 at BTIG
- Bernstein upgrades Vertex, names top 2026 biotech pick
- Vertex Pharmaceuticals upgraded to Outperform from Market Perform at Bernstein
- Vertex Advances Suzetrigine Phase 3 Trial in Diabetic Nerve Pain, Signaling a Broader Growth Story